Across GU cancers, including bladder, renal cell carcinoma, and testicular cancers, Signatera provides highly specific molecular insights that can help clinicians better assess recurrence risk, monitor disease status, and inform individualized patient management strategies. As Regional Director, you will have the opportunity to build and develop a high-performing team, establish strategic partnerships with leading Urologic Oncologists and cancer centers, and help expand access to Signatera's personalized approach to cancer monitoring.